Renee Aguiar-Lucander
Known title: DirectorCIK: 0001591617
Associated companies
Transaction History
| ACIU | ▲ Buy | Grant | 16,568 | $0 | 6/11/2026 | View on chart |
| ACIU | ▲ Buy | Grant | 16,568 | $0 | 6/11/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals
AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals. AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.